The Direct Costs of Dravet's Syndrome before and after Diagnosis Assessment

ČESKÁ, Katarína, Lukas CESKY, Hana OŠLEJŠKOVÁ and Štefánia AULICKÁ. The Direct Costs of Dravet's Syndrome before and after Diagnosis Assessment. Neuropediatrics. STUTTGART: GEORG THIEME VERLAG KG, 2021, vol. 52, No 01, p. 6-11. ISSN 0174-304X. Available from: https://dx.doi.org/10.1055/s-0040-1718518.

Basic information

Original name

The Direct Costs of Dravet's Syndrome before and after Diagnosis Assessment

Authors

ČESKÁ, Katarína (703 Slovakia, belonging to the institution), Lukas CESKY (703 Slovakia), Hana OŠLEJŠKOVÁ (203 Czech Republic, belonging to the institution) and Štefánia AULICKÁ (703 Slovakia, guarantor, belonging to the institution)

Edition

Neuropediatrics, STUTTGART, GEORG THIEME VERLAG KG, 2021, 0174-304X

---

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30103 Neurosciences

Country of publisher

Germany

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 1.696

RIV identification code

RIV/00216224:14110/21:00120783

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1055/s-0040-1718518

UT WoS

000578772900001

Keywords in English

epilepsy; Dravet's syndrome; economic study; costs

Tags

14110320, 14110321, podil, rivok

Tags

International impact, Reviewed

---

Abstract

V originále

The objective of this study was to estimate the direct cost before and after diagnosis assessment in patients with Dravet's syndrome (DS). The basis of the economic study was to calculate the costs of health care before and after diagnosis of DS. We retrospectively evaluated all SCN1A positive patients with phenotype of DS treated in our hospital. Statistical analyses were performed by IBM SPSS Statistics 24.0 software. After the diagnosis of DS, there was a significant decline of health care costs (-85.6%) an average of Euro29.4 +/- 26.1 monthly per patient. We estimated the monthly costs at Euro204.5 +/- 167 (median: Euro193.9, range: Euro35.5-534.4) per patient before DS diagnosis. The major cost was for hospitalization in neurological department: Euro43.3 +/- 52 (median: Euro21.9, range: Euro9.5-179.4) per patient. Minimal cost per patient per months before DS diagnosis was cost of psychological testing/care and complementary rehabilitation (0.13 and 0.6% of total cost). After DS diagnosis, the major cost was focused on nonhospitalization care of patients (64.8%), minimal (Euro0) for genetic testing and major for outpatient care (18%, mean: Euro5.3, median: Euro7). DS results in essential health care utilization and high financial burden before diagnosis elucidation caused by repeated hospitalization and extensive diagnostics tests of "epileptic encephalopathy of unknown etiology." The results of this study point out that early assessment of the diagnosis leads to significant decrease of the financial costs because of adequate therapeutic management and exclusion of redundant diagnostic testing after elucidation of correct diagnosis.